| 1 | Ustekinumab | Evaluation of biological predictive factors of clinical response to ustekinumab 36件: Evaluation of biological predictive factors of clinical response to ustekinumab; Group 2 ustekinumab 130 mg; Group 3: ustekinumab approximately 6 mg/kg; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Prednisone and ustekinumab treatment; Stelara (ustekinumab); Subcutaneous ustekinumab; Ustekinumab; Ustekinumab (6 mg/kg); Ustekinumab (90 mg); Ustekinumab (approximately 6 mg/kg); Ustekinumab + mtx (group 2); Ustekinumab + mtx (group 3); Ustekinumab 130 mg iv; Ustekinumab 180 mg; Ustekinumab 1mg/kg (ip); Ustekinumab 3 mg/kg (ip); Ustekinumab 4.5 mg/kg; Ustekinumab 45 mg; Ustekinumab 6 mg/kg; Ustekinumab 6 mg/kg (ip); Ustekinumab 90 mg; Ustekinumab 90 mg (sc) group 1; Ustekinumab 90 mg (sc) group 2; Ustekinumab 90 mg sc q12w; Ustekinumab 90 mg sc q8w; Ustekinumab 90 milligram (mg); Ustekinumab approximately 6 mg/kg (iv); Ustekinumab dose based on bsa and body weight; Ustekinumab iv; Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp); Ustekinumab iv - responder - ustekinumab 90mg sc (mp); Ustekinumab iv infusion; Ustekinumab liquid in prefilled syringe; Ustekinumab sc; Ustekinumab sc injection; | 1件: D09214 D09214 💬 |
3件: IL12A, IL12B, IL23A 💬 |
African trypanosomiasis 26件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
037 15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬 |